المؤلفون: Ríos-Tamayo, Rafael, Soler, Juan Alfons, García-Sánchez, Ricarda, Pérez Persona, Ernesto, Arnao, Mario, García-Guiñón, Antoni, Domingo, Abel, González-Pardo, Miriam, de la Rubia Comos, Javier, Mateos, Maria-Victoria, GeminiS Study Investigators

مصطلحات موضوعية: Relapsed-refractory multiple myeloma, Real-world, Monoclonal antibodies, Daratumumab, Standard of care, 32 Ciencias Médicas

الوصف: The aim of this study is to describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. ; This study was sponsored by Janssen-Cilag. Janssen-Cilag participated in the study design, data analysis and drafting of the manuscript. All investigators received financial com- pensation for their participation in the study. ; Medicina

العلاقة: http://hdl.handle.net/20.500.12466/4403Test

الإتاحة: https://doi.org/20.500.12466/440310.1080/16078454.2023.2178997Test
https://hdl.handle.net/20.500.12466/4403Test

المؤلفون: Soler, Alfons, Garcia Sanchez, Ricarda, Pérez Persona, Ernesto, Arnao Herraiz, Mario, García-Guiñón, Antoni, Domingo, Abel, González Pardo, Miriam, de la Rubia, Javier, Mateos, María-Victoria, Ríos-Tamayo, Rafael

المساهمون: Ríos-Tamayo R Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. Soler JA Department of Hematology, HospitalUniversitari Parc Taulí de Sabadell, Catalonia, Spain. García-Sánchez R Department of Hematology, Hospital Virgen de la Victoria, Málaga, Spain. Pérez Persona E Department of Hematology, Hospital Universitario de Navarra, Pamplona, Spain. Arnao M Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. García-Guiñón A Department of Hematology, Hospital Universitari Arnau de Vilanova, Lleida, Spain. Domingo A Department of Hematology, Hospital General de Granollers, Granollers, Spain. González-Pardo M Medical Department, Janssen-Cilag España, Spain. de la Rubia J Hospital Universitari i Politècnic La Fe, Valencia, Spain. Hematology Department, Universidad Católica“San Vicente Mártir”, Valencia, Spain. CIBERONC CB16/12/00284,Valencia, Spain. Mateos MV Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Hospital Universitario de Salamanca, Salamanca, Spain, Hospital General de Granollers

المصدر: Scientia

مصطلحات موضوعية: Mieloma múltiple, Anticossos monoclonals, Medicaments - Eficàcia, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, PUBLICATION CHARACTERISTICS::Study Characteristics::Multicenter Study, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, CARACTERÍSTICAS DE PUBLICACIONES::características del estudio::estudio multicéntrico

الوصف: Relapsed-refractory multiple mieloma; Monoclonal antibodies; Observational multicenter study ; Mieloma múltiple recidivant-refractari; Anticossos monoclonals; Estudi observacional multicèntric ; Mieloma múltiple recidivante-refractario; Anticuerpos monoclonales; Estudio multicéntrico observacional ; Objectives: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. Methods: This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. Results: A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. Conclusions: The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. Keywords: Relapsed-refractory multiple myeloma; daratumumab; monoclonal antibodies; real-world; standard of care.

وصف الملف: application/pdf

العلاقة: Hematology;28(1); https://doi.org/10.1080/16078454.2023.2178997Test; Ríos-Tamayo R, Soler JA, García-Sánchez R, Pérez Persona E, Arnao M, García-Guiñón A, et al. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study. Hematology. 2023 Dec;28(1):2178997.; https://hdl.handle.net/11351/9425Test

الإتاحة: https://doi.org/10.1080/16078454.2023.2178997Test
https://hdl.handle.net/11351/9425Test

المؤلفون: Ríos-Tamayo, R., Soler, Joan Alfons, García-Sánchez, Ricarda, Pérez Persona, Ernesto, Arnao‐Herráiz, Mario, Garcia-Guiñon, Antonio, Domingo, Abel, González-Pardo, Miriam, Rubia, Javier de la, Mateos, Maria Victoria

المساهمون: Janssen-Cilag, Consejo Superior de Investigaciones Científicas https://ror.org/02gfc7t72Test

مصطلحات موضوعية: Relapsed-refractory multiple myeloma, Real-world monoclonal, Antibodies, Daratumumab, Standard of care

الوصف: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. ; This study was sponsored by Janssen-Cilag. Janssen-Cilag participated in the study design, data analysis and drafting of the manuscript ; Peer reviewed

وصف الملف: application/msword

العلاقة: Publisher's version; Ríos-Tamayo, R.; Soler, Joan Alfons; García-Sánchez, Ricarda; Pérez Persona, Ernesto; Arnao‐Herráiz, Mario; Garcia-Guiñon, Antonio; Domingo, Abel; González-Pardo, Miriam; Rubia, Javier de la; Mateos, Maria Victoria. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study. http://dx.doi.org/10.1080/16078454.2023.2178997Test . http://hdl.handle.net/10261/337306Test; https://doi.org/10.6084/m9.figshare.22794424.v1Test; Sí; Ríos-Tamayo, R.; Soler, Joan Alfons; García-Sánchez, Ricarda; Pérez Persona, Ernesto; Arnao‐Herráiz, Mario; Garcia-Guiñon, Antonio; Domingo, Abel; González-Pardo, Miriam; Rubia, Javier de la; Mateos, Maria Victoria; 2023; A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study [Dataset]; Taylor & Francis; https://doi.org/10.6084/m9.figshare.22794424.v1Test; http://hdl.handle.net/10261/360735Test

الإتاحة: https://doi.org/10.6084/m9.figshare.22794424.v110.1080/16078454.2023.2178997Test
http://hdl.handle.net/10261/360735Test

المؤلفون: González-López, Tomás José, Bermejo-Vega, Nuria, Cardesa-Cabrera, Rocío, Martínez-Robles, Violeta, Aguilar-Monserrate, Gerardo, Pérez-Segura, Gloria, Domingo, Abel, Luis-Navarro, Josefa, Lakhwani, Sunil, Acedo, Natalia, Lozano, María Luisa, Bernat, Silvia, Torres-Tienza, Ana, Ruano, Ana, Jarque, Isidro, Galán, Pilar, Benet, Carmen, Marcellini, Shally, Jimenez-Bárcenas, Reyes, Martínez-Carballeira, Daniel, De Miguel-Llorente, Dunia, Perona-Blázquez, Alvaro, Gonzalez-Gascón, Isabel, Lopez-Ansoar, Elsa, Alonso-Alonso, José María, Bengochea-Casado, María Luisa, Díaz-Gálvez, Francisco Javier, Moretó, Ana, Moreno-Jiménez, Gemma, Hernández-Martin, Roberto, de Cabo, Erik, Dávila-Valls, Julio, Cuesta, Amalia, Pastoriza, Carmen, Hermida-Fernández, Gerardo Julio, García, Covadonga, Pozas-Mañas, Miguel Angel, Aguilar, Carlos, Fernandez-Jimenez, Dolores, Navas-Elorza, Begoña, López-Santamaría Castro, Carolina, Lorenzo, Alvaro, Ortín, Xavier, García, Marta, Piernas, Sonia, Díaz-Santa, Johana, Soto, Inmaculada, Provan, Drew, García-Donas Gabaldón, Gloria

المصدر: Blood; 20240101, Issue: Preprints

مستخلص: -Similar to clinical trial results, fostamatinib has demonstrated a high efficacy rate for ITP in daily clinical practice conditions.-Fostamatinib is a well-tolerated drug with a very low rate of thrombotic events associated with its use.

المؤلفون: Gonzalez-Lopez, Tomas Jose, Perez Segura, Gloria, Domingo, Abel, Lopez Ansoar, Elsa, Diaz Galvez, Francisco Javier, Jimenez Barcenas, Reyes, Martinez Carballeira, Daniel, De Miguel Llorente, Dunia, Perona Blazquez, Alvaro, Aguilar-Monserrate, Gerardo, Dávila-Valls, Julio, Gonzalez Gascon, Isabel, Cuesta, Amalia, Bengochea Casado, María Luisa, Hermida Fernandez, Gerardo Julio, Alonso Alonso, Jose Maria, Pozas Mañas, Miguel Angel, Torres-Tienza, Ana, Aguilar, Carlos, Fernandez-Jimenez, Dolores, Soto, Inmaculada, Bernat, Silvia

المصدر: Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2591-2591, 1p

مستخلص: Background: Fostamatinib is a splenic tyrosine kinase (SYK) inhibitor that prevents antibody-mediated platelet destruction. This drug has demonstrated to be effective and safe in immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens in clinical practice. Here we evaluated the efficacy and safety of eltrombopag in ITP in a real-world setting.

المؤلفون: Díaz Lozano, Rita Margarita, Flores Quintero, Erika Smith, García Fernández, Domingo Abel, Luna Solano, Claudia Patricia, Rua Cadavid, Carlos Mario

المساهمون: Gómez Vargas, Ricardo Cesar, Asesor

مصطلحات موضوعية: Radio de Microondas, Centro de Operaciones de Red, NOC, Telecomunicaciones, Orden de Servicio, Trabajo de Grado - Especialización

الوصف: Diseño de Propuesta para la creación de la Empresa Red de Comunicaciones Colombia, proyecto que tiene como objetivo brindar un recurso Humano calificado, capaz de llevar a cabo funciones de Monitoreo, Detección y Gestión de Fallas en Radios de Microondas, que logre cumplir los Acuerdos de Nivel de Servicio establecidos por las compañías de Telecomunicaciones, disminuyendo de esta manera los riesgos en cuanto a sanciones y manteniendo la Calidad del servicio que se brinda a los Usuarios. El desarrollo de éste, como caso particular de estudio, se tiene el (NOC) Centro de Gestión de Fallas de Claro Móvil, en donde por su alta demanda de usuarios tienen instalados radios de Microondas para el buen desempeño de sus redes Móviles, sin embargo de acuerdo a información obtenida del monitoreo que se tiene actualmente con respecto a las fallas que se generan sobre los mismos, no se cuenta con un tiempo óptimo de detección y las recientes estadísticas revelan que los recursos a cargo de esta función pueden tardar en promedio unos 40 minutos en detectar y escalar cualquier evento que afecte el servicio, generando altos tiempos de indisponibilidad y según los Acuerdos de Nivel del Servicio establecidos por la compañía de Claro estos tiempos no deben superar más de 20 minutos para su diagnóstico y debido escalamiento, lo que al momento no se está cumpliendo.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10823/928Test; instname:Politécnico Grancolombiano; reponame:Alejandría Repositorio Comunidad; repourl:http://alejandria.poligran.edu.coTest

الإتاحة: http://hdl.handle.net/10823/928Test

المؤلفون: Novelli, Silvana, Zamora, Carlos, Vidal, Silvia, Valcarcel, David, Sanchez-Gonzalez, Blanca, Garcia-Pallarols, Francesc, Rodriguez, Yva, Domingo, Abel, Canet Maldonado, Marta, Olivera, Pável E

المصدر: Blood; November 2022, Vol. 140 Issue: Supplement 1 p2685-2686, 2p

المؤلفون: Maffioli, Margherita, Camós, Mireia, Gaya, Anna, Hernández-Boluda, Juan-Carlos, Álvarez-Larrán, Alberto, Domingo, Abel, Granell, Miquel, Guillem, Vicent, Vallansot, Rolando, Costa, Dolors, Bellosillo, Beatriz, Colomer, Dolors, Cervantes, Francisco

المصدر: Leukemia Research ; volume 35, issue 8, page 1014-1019 ; ISSN 0145-2126

الإتاحة: https://doi.org/10.1016/j.leukres.2010.12.004Test
https://api.elsevier.com/content/article/PII:S0145212610005965?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0145212610005965?httpAccept=text/plainTest

المؤلفون: Alvarez-Larrán, Alberto, Arellano-Rodrigo, Eduardo, Reverter, Juan Carlos, Domingo, Abel, Villamor, Neus, Colomer, Dolors, Cervantes, Francisco

المصدر: Annals of Hematology ; volume 87, issue 4, page 269-276 ; ISSN 0939-5555 1432-0584

مصطلحات موضوعية: Hematology, General Medicine

الإتاحة: https://doi.org/10.1007/s00277-007-0386-3Test

المؤلفون: Cervantes, Francisco, Alvarez‐Larrán, Alberto, Domingo, Abel, Arellano‐Rodrigo, Eduardo, Montserrat, Emili

المصدر: British Journal of Haematology ; volume 129, issue 6, page 771-775 ; ISSN 0007-1048 1365-2141

الوصف: Summary Androgens are considered the treatment of choice for the anaemia of myelofibrosis with myeloid metaplasia (MMM). Good results have been reported in a few patients treated with danazol, a synthetic attenuated androgen. The long‐term efficacy and tolerability of danazol as treatment for the anaemia of MMM was evaluated in 30 patients, who received 600 mg/d, with progressive tapering to the minimum effective dose in the responders after 6 months. Complete response (CR) was defined as transfusion cessation with normal Hb and partial response (PR) as an Hb increase ≥1·5 g/dl with transfusion‐independent Hb values >10 g/dl maintained for at least 8 weeks. Median follow‐up was 20·5 months (range: 3·5–58 months). Response was achieved in 11 patients (37%), including eight CRs and three PRs. Median time to response was 5 months (range: 1–9 months). Four patients stopped responding at 6–24 months, two responders discontinued treatment because of toxicity, and five maintained response at 3·5–42 months. Pretreatment variables associated with response were lack of transfusion requirement ( P = 0·001) and higher Hb at treatment start ( P = 0·02). Toxicity was usually moderate, leading to treatment withdrawal in only two cases. Danazol is effective and well tolerated in a substantial proportion of MMM patients with anaemia.

الإتاحة: https://doi.org/10.1111/j.1365-2141.2005.05524.xTest